The important question around drug comparison (sema vs tirz vs brand) is practical: what is actually known, what remains uncertain, and what safeguards a licensed clinician and pharmacy process add before anyone treats it as an option.
A patient I’ll call Sarah sat in a telehealth consult last October with two browser tabs open: one showing Wegovy pricing at her local CVS ($1,348 out of pocket), the other a compounded tirzepatide option at roughly a third of that. Her question was simple and completely reasonable: “Which drug should I actually be on, and does it matter where I get it?” Her prescriber spent 40 minutes walking through what I’m about to cover here, because there’s no honest short answer.
Two Molecules, One Overlapping Mechanism
Both semaglutide and tirzepatide slow gastric emptying, blunt appetite through central nervous system signaling, and require careful dose escalation to keep side effects tolerable. The key pharmacological difference is structural. Semaglutide activates only the GLP-1 receptor. Tirzepatide hits both GLP-1 and GIP receptors, a dual agonist design that appears to produce somewhat greater metabolic effects in most (not all) patients.
Both have half-lives around seven days, which is why weekly dosing works.
The trial numbers people cite most often:
- STEP-1 (Wilding et al., NEJM 2021): semaglutide 2.4 mg produced mean weight loss of 14.9% over 68 weeks.
- SURMOUNT-1 (Jastreboff et al., NEJM 2022): tirzepatide at 5 mg, 10 mg, and 15 mg produced mean reductions of 15.0%, 19.5%, and 20.9% over 72 weeks.
Population averages are useful but incomplete. STEP-1 had individual responders ranging from around 5% to over 25% weight loss. The same spread exists in the SURMOUNT data. If you’re the person who responds brilliantly to semaglutide at 2.4 mg, the theoretical superiority of tirzepatide at 15 mg is academic. And SURMOUNT-5 (presented 2024) did show tirzepatide ahead of semaglutide in a direct head-to-head comparison over 72 weeks, but “ahead on average” is not the same thing as “better for you specifically.”
My honest take: tirzepatide probably has a meaningful edge for the average patient seeking maximum weight reduction. But choosing a GLP-1 is more like choosing a blood pressure medication than choosing a better iPhone. The best one is the one your body tolerates, your insurance covers (or your wallet survives), and you actually inject every week for years.
See also: Digital Communication Technology Explained
Branded vs. Compounded: What’s Actually Different
This is where confusion multiplies. The active ingredient in compounded tirzepatide is tirzepatide. The active ingredient in Zepbound or Mounjaro is also tirzepatide. Same molecule. The differences live at the manufacturing, regulatory, and pricing layers.
Branded products (Mounjaro, Zepbound, Ozempic, Wegovy) are FDA-approved finished drugs. Eli Lilly or Novo Nordisk manufactures them under cGMP standards, with established labeling and post-marketing surveillance systems. If something goes wrong at scale, there’s a traceable recall infrastructure.
Compounded preparations come from 503A pharmacies (patient-specific prescriptions) or 503B outsourcing facilities (which can produce larger batches and are subject to FDA inspection under cGMP-like standards). These are not FDA-evaluated for safety, efficacy, or quality in the way branded products are. Oversight comes from state pharmacy boards, federal 503A/503B requirements, and individual prescriber judgment.
The analogy I use: branded is like buying a car from the manufacturer’s dealership with full warranty. Compounded is like buying the same engine rebuilt by a licensed mechanic. The engine can be excellent, but the quality assurance infrastructure is different, and you need to vet the mechanic.
Patients considering compounded options should look at: state licensure, third-party accreditation where applicable, whether a real clinician evaluates you (not just a form), and transparent pricing. A deeper drug comparison (sema vs tirz vs brand) covering protocol-level details, monitoring labs, and the practical questions that come up between visits is available for patients doing that homework.
The Titration Schedule (and Why People Rush It)
Standard tirzepatide titration starts at 2.5 mg weekly for four weeks. This is the tolerance phase. You shouldn’t expect meaningful weight loss here. Think of it as your GI tract’s orientation week.
Then 5 mg for four weeks, which is where most people first notice real appetite suppression. After that, step-ups to 7.5, 10, 12.5, and 15 mg happen at four-week intervals based on response and tolerance. Maximum labeled dose for weight management is 15 mg.
| Phase | Dose | Duration | What to Expect | |—|—|—|—| | Initiation | 2.5 mg weekly | Weeks 1-4 | GI adjustment, minimal weight change | | Step 1 | 5 mg weekly | Weeks 5-8 | First real appetite suppression | | Step 2 | 7.5 mg weekly | Weeks 9-12 | Some patients hold here if response is solid | | Step 3 | 10 mg weekly | Weeks 13-16 | Common long-term maintenance dose | | Step 4 | 12.5 mg weekly | Weeks 17-20 | For patients whose response plateaus | | Step 5 | 15 mg weekly | Week 21+ | Maximum labeled dose; not everyone needs it |
Many patients stabilize at 5 to 10 mg once they hit their goal weight. Not everyone needs to climb to 15.
One practical note about compounded preparations: they sometimes allow intermediate doses like 6.25 or 8.75 mg, which branded autoinjectors don’t offer. For patients who get crushed by nausea at each step-up, those half-steps can be the difference between staying on therapy and abandoning it.
Side Effects: What the Numbers Look Like in Practice
GI symptoms dominate. Nausea hits 30 to 45% of trial participants, followed by diarrhea (15 to 23%), constipation (10 to 17%), vomiting (8 to 13%), and reflux (7 to 12%, probably underreported).
The pattern is predictable. Side effects cluster in the first four to eight weeks and spike again with each dose increase. They usually peak a few days after a step-up and fade over two to three weeks at a stable dose.
| Symptom | Frequency | Timing | What Helps | |—|—|—|—| | Nausea | 30-45% | Early weeks, dose increases | Smaller meals, low fat, antiemetic if persistent | | Diarrhea | 15-23% | Variable | Hydration, electrolytes, bland diet short-term | | Constipation | 10-17% | Often as GI motility slows | 25-35 g fiber daily, hydration, magnesium if cleared | | Vomiting | 8-13% | First weeks, escalations | Hold dose, call prescriber if it persists | | Reflux | 7-12% | Throughout | No food within 3 hours of bed, raise head of bed | | Fatigue | Variable | First weeks | Usually resolves; check ferritin, B12, TSH if it lingers |
Serious labeled risks include pancreatitis, gallbladder disease, severe hypoglycemia (especially with concurrent insulin or sulfonylureas), kidney injury from dehydration, and a boxed warning for medullary thyroid carcinoma based on rodent data.
Baseline labs worth ordering before starting: CMP (liver and kidney function), HbA1c and fasting glucose, lipid panel, TSH, lipase (especially with any pancreatitis history), and CBC. Recheck at 12 to 16 weeks, then roughly every six months once stable. Severe abdominal pain radiating to the back means call your clinician immediately to rule out pancreatitis.
What Actually Drives the Decision
The factors I see patients weigh, in roughly this order:
Cost and access. This is the elephant. Branded Zepbound with insurance? Great, if your plan covers it. Cash-pay branded? North of $1,000/month. Cash-pay compounded? Significantly less, but with the regulatory trade-offs described above. For many patients, cost isn’t a preference; it’s a constraint.
Diabetes status. Mounjaro and Ozempic carry FDA labels for type 2 diabetes. Zepbound and Wegovy are labeled for chronic weight management. Insurance coverage for the weight management indications usually requires BMI of 30+, or 27+ with qualifying comorbidities like hypertension or dyslipidemia.
Prior GLP-1 experience. Patients who tolerated semaglutide well but plateaued sometimes switch to tirzepatide for additional weight loss. Patients who couldn’t tolerate semaglutide need careful clinician discussion before trying tirzepatide, since the overlapping GLP-1 mechanism means GI intolerance may recur.
Consistency. The boring truth is that the molecule a patient will actually inject every week, paired with reasonable dietary and movement habits, outperforms the theoretically superior molecule sitting unused in a refrigerator.
When You Need a Clinician, Not Google
Before starting: talk to a clinician if you have personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, history of pancreatitis, severe gastroparesis, significant liver impairment, current or planned pregnancy, or if you’re on insulin or sulfonylureas without active diabetes management.
During therapy: contact a clinician for severe persistent abdominal pain (especially radiating to the back), dehydration signs from vomiting or diarrhea, vision changes (particularly diabetic patients), persistent severe reflux, allergic reaction signs, or anything that feels distinctly outside normal titration discomfort.
Routine check-ins every 12 to 16 weeks during active titration, then every six months once stable, is a reasonable rhythm.
Frequently Asked Questions
Is tirzepatide more effective than semaglutide?
On a population level, yes. SURMOUNT-5 data presented in 2024 showed greater mean weight reduction with tirzepatide versus semaglutide over 72 weeks. But individual response varies substantially, and clinical selection depends on tolerability, cost, access, and patient history.
What are the practical differences between the molecules?
Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist. The added GIP activity likely contributes to the weight loss and metabolic differences observed in head-to-head data.
Can I switch between them?
Yes, under clinician guidance. The standard approach is to start the new molecule at its lowest dose rather than trying to dose-match, so you can reassess tolerance from scratch.
Which has more side effects?
Both share GLP-1-mediated GI side effects, primarily nausea, diarrhea, and constipation. Reported rates in trial data are broadly similar. Individual variation matters more than population averages here.
Is branded better than compounded?
Branded products carry FDA manufacturing oversight, established labeling, and post-marketing surveillance. Compounded preparations are not FDA-approved. The question isn’t really “better” as a category; it’s which option fits your clinical context, budget, and access situation.
How do I decide which to start?
Work with a clinician who reviews your full history. The decision usually weighs diabetes status, BMI, prior medication tolerability, cost, and logistics.
Do compounded versions have the same side effects?
The active ingredient is the same, so the side effect profile driven by the molecule itself is expected to be similar. Differences in formulation (concentration, excipients) could theoretically affect tolerability, which is one reason clinician oversight and pharmacy vetting matter.
Important regulatory note. Compounded tirzepatide is not FDA-approved. It is prepared by licensed 503A or 503B pharmacies for individual patients based on a prescriber’s clinical judgment. Compounded preparations are not evaluated by the FDA for safety, efficacy, or quality the way branded products are. Research suggests outcomes vary between patients, and any decision to begin, modify, or discontinue therapy should occur in coordination with a licensed clinician who can review your medical history, current medications, and laboratory values.
